InvestingPro Fair Value model captures 40% downside in Spyre Therapeutics

InvestingPro's Fair Value model has revealed a concerning 40% downside for Spyre Therapeutics, indicating potential challenges ahead for the company. This significant drop in projected value raises alarms for investors, suggesting that the stock may be overvalued and could face further declines. Understanding these insights is crucial for stakeholders as they navigate their investment strategies in a volatile market.